NRx Pharmaceuticals, Inc.
NRXP•NASDAQ•Healthcare•Biotechnology

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOJonathan Javitt
Founded2015
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitewww.nrxpharma.com
Phone484 254 6134
Address
1201 Orange Street, Suite 600 Wilmington, Delaware 19801 United States

Corporate Identifiers

CIK0001719406
CUSIP629444209
ISINUS6294442099
EIN82-2844431
SIC2834

Leadership Team & Key Executives

Matthew Patrick Duffy
Chief Business Officer and Co-Chief Executive Officer of Hope Therapeutics
Dr. Jonathan C. Javitt M.D., M.P.H.
Co-Founder, Chief Scientist Officer, Chairman and Interim Chief Executive Officer
Michael S. Abrams
Chief Financial Officer
Dr. Riccardo Panicucci Ph.D.
Chief Manufacturing and Technology Officer
Suzanne Messere
Investor Relations
Dr. Philip T. Lavin Ph.D.
Chief Methodologist